Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients

Akshay S. Desai, John J V McMurray, Milton Packer, Karl Swedberg, Jean L. Rouleau, Fabian Chen, Jianjian Gong, Adel R. Rizkala, Abdel Brahimi, Brian Claggett, Peter V. Finn, Loren Howard Hartley, Jiankang Liu, Martin Lefkowitz, Victor Shi, Michael R. Zile, Scott D. Solomon

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

Aims: The angiotensin-receptor-neprilysin inhibitor (ARNI) LCZ696 reduced cardiovascular deaths and all-cause mortality compared with enalapril in patients with chronic heart failure in the prospective comparison of ARNI with an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. To more completely understand the components of this mortality benefit, we examined the effect of LCZ696 on mode of death. Methods and results: PARADIGM-HF was a prospective, double-blind, randomized trial in 8399 patients with chronic heart failure, New York Heart Association Class II-IV symptoms, and left ventricular ejection fraction ≤40% receiving guideline-recommended medical therapy and followed for a median of 27 months. Mode of death was adjudicated by a blinded clinical endpoints committee. The majority of deaths were cardiovascular (80.9%), and the risk of cardiovascular death was significantly reduced by treatment with LCZ (hazard ratio, HR 0.80, 95% CI 0.72-0.89, P < 0.001). Among cardiovascular deaths, both sudden cardiac death (HR 0.80, 95% CI 0.68-0.94, P = 0.008) and death due to worsening heart failure (HR 0.79, 95% CI 0.64-0.98, P = 0.034) were reduced by treatment with LCZ696 compared with enalapril. Deaths attributed to other cardiovascular causes, including myocardial infarction and stroke, were infrequent and distributed evenly between treatment groups, as were non-cardiovascular deaths. Conclusions: LCZ696 was superior to enalapril in reducing both sudden cardiac deaths and deaths from worsening heart failure, which accounted for the majority of cardiovascular deaths. Clinical Trial Registration: https://clinicaltrials.gov/, NCT01035255.

Original languageEnglish (US)
Pages (from-to)1990-1997
Number of pages8
JournalEuropean Heart Journal
Volume36
Issue number30
DOIs
StatePublished - Aug 7 2015

Fingerprint

Neprilysin
Angiotensin Receptors
Enalapril
Heart Failure
Sudden Cardiac Death
Mortality
LCZ 696
Therapeutics
Angiotensin-Converting Enzyme Inhibitors
Stroke Volume
Cause of Death
Stroke
Myocardial Infarction
Clinical Trials
Guidelines
Morbidity

Keywords

  • Angiotensin-receptor blocker
  • Clinical trial
  • Heart failure
  • Mortality
  • Neprilysin inhibition
  • Pharmacotherapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Desai, A. S., McMurray, J. J. V., Packer, M., Swedberg, K., Rouleau, J. L., Chen, F., ... Solomon, S. D. (2015). Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. European Heart Journal, 36(30), 1990-1997. https://doi.org/10.1093/eurheartj/ehv186

Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. / Desai, Akshay S.; McMurray, John J V; Packer, Milton; Swedberg, Karl; Rouleau, Jean L.; Chen, Fabian; Gong, Jianjian; Rizkala, Adel R.; Brahimi, Abdel; Claggett, Brian; Finn, Peter V.; Hartley, Loren Howard; Liu, Jiankang; Lefkowitz, Martin; Shi, Victor; Zile, Michael R.; Solomon, Scott D.

In: European Heart Journal, Vol. 36, No. 30, 07.08.2015, p. 1990-1997.

Research output: Contribution to journalArticle

Desai, AS, McMurray, JJV, Packer, M, Swedberg, K, Rouleau, JL, Chen, F, Gong, J, Rizkala, AR, Brahimi, A, Claggett, B, Finn, PV, Hartley, LH, Liu, J, Lefkowitz, M, Shi, V, Zile, MR & Solomon, SD 2015, 'Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients', European Heart Journal, vol. 36, no. 30, pp. 1990-1997. https://doi.org/10.1093/eurheartj/ehv186
Desai, Akshay S. ; McMurray, John J V ; Packer, Milton ; Swedberg, Karl ; Rouleau, Jean L. ; Chen, Fabian ; Gong, Jianjian ; Rizkala, Adel R. ; Brahimi, Abdel ; Claggett, Brian ; Finn, Peter V. ; Hartley, Loren Howard ; Liu, Jiankang ; Lefkowitz, Martin ; Shi, Victor ; Zile, Michael R. ; Solomon, Scott D. / Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. In: European Heart Journal. 2015 ; Vol. 36, No. 30. pp. 1990-1997.
@article{9c743ccc3c8249aa82ad41827dfc63bb,
title = "Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients",
abstract = "Aims: The angiotensin-receptor-neprilysin inhibitor (ARNI) LCZ696 reduced cardiovascular deaths and all-cause mortality compared with enalapril in patients with chronic heart failure in the prospective comparison of ARNI with an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. To more completely understand the components of this mortality benefit, we examined the effect of LCZ696 on mode of death. Methods and results: PARADIGM-HF was a prospective, double-blind, randomized trial in 8399 patients with chronic heart failure, New York Heart Association Class II-IV symptoms, and left ventricular ejection fraction ≤40{\%} receiving guideline-recommended medical therapy and followed for a median of 27 months. Mode of death was adjudicated by a blinded clinical endpoints committee. The majority of deaths were cardiovascular (80.9{\%}), and the risk of cardiovascular death was significantly reduced by treatment with LCZ (hazard ratio, HR 0.80, 95{\%} CI 0.72-0.89, P < 0.001). Among cardiovascular deaths, both sudden cardiac death (HR 0.80, 95{\%} CI 0.68-0.94, P = 0.008) and death due to worsening heart failure (HR 0.79, 95{\%} CI 0.64-0.98, P = 0.034) were reduced by treatment with LCZ696 compared with enalapril. Deaths attributed to other cardiovascular causes, including myocardial infarction and stroke, were infrequent and distributed evenly between treatment groups, as were non-cardiovascular deaths. Conclusions: LCZ696 was superior to enalapril in reducing both sudden cardiac deaths and deaths from worsening heart failure, which accounted for the majority of cardiovascular deaths. Clinical Trial Registration: https://clinicaltrials.gov/, NCT01035255.",
keywords = "Angiotensin-receptor blocker, Clinical trial, Heart failure, Mortality, Neprilysin inhibition, Pharmacotherapy",
author = "Desai, {Akshay S.} and McMurray, {John J V} and Milton Packer and Karl Swedberg and Rouleau, {Jean L.} and Fabian Chen and Jianjian Gong and Rizkala, {Adel R.} and Abdel Brahimi and Brian Claggett and Finn, {Peter V.} and Hartley, {Loren Howard} and Jiankang Liu and Martin Lefkowitz and Victor Shi and Zile, {Michael R.} and Solomon, {Scott D.}",
year = "2015",
month = "8",
day = "7",
doi = "10.1093/eurheartj/ehv186",
language = "English (US)",
volume = "36",
pages = "1990--1997",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "30",

}

TY - JOUR

T1 - Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients

AU - Desai, Akshay S.

AU - McMurray, John J V

AU - Packer, Milton

AU - Swedberg, Karl

AU - Rouleau, Jean L.

AU - Chen, Fabian

AU - Gong, Jianjian

AU - Rizkala, Adel R.

AU - Brahimi, Abdel

AU - Claggett, Brian

AU - Finn, Peter V.

AU - Hartley, Loren Howard

AU - Liu, Jiankang

AU - Lefkowitz, Martin

AU - Shi, Victor

AU - Zile, Michael R.

AU - Solomon, Scott D.

PY - 2015/8/7

Y1 - 2015/8/7

N2 - Aims: The angiotensin-receptor-neprilysin inhibitor (ARNI) LCZ696 reduced cardiovascular deaths and all-cause mortality compared with enalapril in patients with chronic heart failure in the prospective comparison of ARNI with an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. To more completely understand the components of this mortality benefit, we examined the effect of LCZ696 on mode of death. Methods and results: PARADIGM-HF was a prospective, double-blind, randomized trial in 8399 patients with chronic heart failure, New York Heart Association Class II-IV symptoms, and left ventricular ejection fraction ≤40% receiving guideline-recommended medical therapy and followed for a median of 27 months. Mode of death was adjudicated by a blinded clinical endpoints committee. The majority of deaths were cardiovascular (80.9%), and the risk of cardiovascular death was significantly reduced by treatment with LCZ (hazard ratio, HR 0.80, 95% CI 0.72-0.89, P < 0.001). Among cardiovascular deaths, both sudden cardiac death (HR 0.80, 95% CI 0.68-0.94, P = 0.008) and death due to worsening heart failure (HR 0.79, 95% CI 0.64-0.98, P = 0.034) were reduced by treatment with LCZ696 compared with enalapril. Deaths attributed to other cardiovascular causes, including myocardial infarction and stroke, were infrequent and distributed evenly between treatment groups, as were non-cardiovascular deaths. Conclusions: LCZ696 was superior to enalapril in reducing both sudden cardiac deaths and deaths from worsening heart failure, which accounted for the majority of cardiovascular deaths. Clinical Trial Registration: https://clinicaltrials.gov/, NCT01035255.

AB - Aims: The angiotensin-receptor-neprilysin inhibitor (ARNI) LCZ696 reduced cardiovascular deaths and all-cause mortality compared with enalapril in patients with chronic heart failure in the prospective comparison of ARNI with an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. To more completely understand the components of this mortality benefit, we examined the effect of LCZ696 on mode of death. Methods and results: PARADIGM-HF was a prospective, double-blind, randomized trial in 8399 patients with chronic heart failure, New York Heart Association Class II-IV symptoms, and left ventricular ejection fraction ≤40% receiving guideline-recommended medical therapy and followed for a median of 27 months. Mode of death was adjudicated by a blinded clinical endpoints committee. The majority of deaths were cardiovascular (80.9%), and the risk of cardiovascular death was significantly reduced by treatment with LCZ (hazard ratio, HR 0.80, 95% CI 0.72-0.89, P < 0.001). Among cardiovascular deaths, both sudden cardiac death (HR 0.80, 95% CI 0.68-0.94, P = 0.008) and death due to worsening heart failure (HR 0.79, 95% CI 0.64-0.98, P = 0.034) were reduced by treatment with LCZ696 compared with enalapril. Deaths attributed to other cardiovascular causes, including myocardial infarction and stroke, were infrequent and distributed evenly between treatment groups, as were non-cardiovascular deaths. Conclusions: LCZ696 was superior to enalapril in reducing both sudden cardiac deaths and deaths from worsening heart failure, which accounted for the majority of cardiovascular deaths. Clinical Trial Registration: https://clinicaltrials.gov/, NCT01035255.

KW - Angiotensin-receptor blocker

KW - Clinical trial

KW - Heart failure

KW - Mortality

KW - Neprilysin inhibition

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=84939603387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939603387&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehv186

DO - 10.1093/eurheartj/ehv186

M3 - Article

C2 - 26022006

AN - SCOPUS:84939603387

VL - 36

SP - 1990

EP - 1997

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 30

ER -